{"id":"379cea5b-ef8c-4bca-a8e9-dac76fb4710d","kind":"companies","code":"UB-C3525","name":"Phil Rivers","nameBasis":"source-english","summary":"Provider of solutions for AI pharmaceutical research and development.","description":"Zheyuan Technology is an AI pharmaceutical research and development solutions provider","country":"China","category":null,"originalName":"哲源科技","eventDate":null,"website":"https://www.philrivers.com/","sourceUpdatedAt":"2026-10-03T00:00:00.000Z","englishUpdatedAt":"2026-10-20T18:23:29.560Z","reviewedAt":"2026-10-20T18:23:29.560Z","snapshotAt":"2026-10-20T18:05:01.520Z","sourceHash":"1c00191b9afe13cf2d0f0c507c4b5e1bd8f064797868105329f6907d4482131a","companyId":null,"foundedYear":null,"logoUrl":null,"originalText":"AI医药研发解决方案提供商\n\n哲源科技是一家AI医药研发解决方案提供商","sources":[],"related":[{"id":"b515d63e-5a11-48b6-91c5-b93a47540d5e","kind":"news","code":"b515d63e-5a11-48b6-91c5-b93a47540d5e","name":"Phil Rivers completes strategic financing","nameBasis":"translated-title","summary":"","description":"","country":null,"category":null,"originalName":"哲源科技完成战略投资融资","eventDate":"2024-12-12T00:00:00.000Z","website":null,"sourceUpdatedAt":"2026-10-14T21:00:16.423Z","englishUpdatedAt":"2026-10-15T17:19:59.889Z","reviewedAt":"2026-10-15T17:19:59.889Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"2d002dc3ac7ad89ca760f1694a9fda8420f05d438bc56c21fa90246f8dc27f64","companyId":"379cea5b-ef8c-4bca-a8e9-dac76fb4710d","foundedYear":null,"logoUrl":null,"path":"/news/b515d63e-5a11-48b6-91c5-b93a47540d5e"},{"id":"3d5c8a2a-7746-46ea-adaf-535bc0ef27ae","kind":"news","code":"3d5c8a2a-7746-46ea-adaf-535bc0ef27ae","name":"Phil Rivers raises RMB 100 million in Series A financing","nameBasis":"translated-title","summary":"","description":"","country":null,"category":null,"originalName":"哲源科技完成1亿人民币A轮融资","eventDate":"2022-06-15T00:00:00.000Z","website":null,"sourceUpdatedAt":"2026-10-14T11:38:22.624Z","englishUpdatedAt":"2026-10-15T17:19:59.417Z","reviewedAt":"2026-10-15T17:19:59.417Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"194e86a2847d916a92d0da9a0ad34d3ae7b1282522683af4ca1b00c9bddea053","companyId":"379cea5b-ef8c-4bca-a8e9-dac76fb4710d","foundedYear":null,"logoUrl":null,"path":"/news/3d5c8a2a-7746-46ea-adaf-535bc0ef27ae"},{"id":"0c87ff00-553b-47b8-bb6e-472130f54a45","kind":"news","code":"0c87ff00-553b-47b8-bb6e-472130f54a45","name":"Phil Rivers raises RMB 200 million in Series A+ financing","nameBasis":"translated-title","summary":"On 2026-03-12, according to Xiniu Data, Phil Rivers completed Series A+ financing, raising RMB 200 million. Investors were Shengxiang Biotechnology, Shengweirongquan, Zhangjiangketou, Zhongkechuangxing.","description":"","country":null,"category":null,"originalName":"哲源科技完成A+轮融资，金额2亿人民币","eventDate":"2026-03-12T00:00:00.000Z","website":null,"sourceUpdatedAt":"2026-10-18T17:18:23.135Z","englishUpdatedAt":"2026-10-20T18:21:37.066Z","reviewedAt":"2026-10-20T18:21:37.066Z","snapshotAt":"2026-10-20T18:19:32.670Z","sourceHash":"8121942cf7a0885241b493d0291e80f906b3dcdf8e7d779291ab4e37da44aacd","companyId":"379cea5b-ef8c-4bca-a8e9-dac76fb4710d","foundedYear":null,"logoUrl":null,"path":"/news/0c87ff00-553b-47b8-bb6e-472130f54a45"},{"id":"2d71f315-d801-4dda-a133-bdf72aa26d08","kind":"products","code":"UB-D471","name":"Zheyuan Technology","nameBasis":"transliterated","summary":"Zheyuan Technology provides AI pharmaceutical R&D solutions. Incubated by the Chinese Academy of Sciences’ Institute of Computing Technology, it is a platform company using digital life technology for pharmaceutical innovation. Its digital twins of life functions systematically propose new tumor targets, evaluate promising indications and predict responding patients. It aims to build a digital drug testing ground that overcomes biochemical bottlenecks, improves drug R&D productivity, clinical trial success and treatment effectiveness, and introduces a new R&D paradigm to protect human health. It holds high-value intellectual property in new targets, indications and companion diagnostics.","description":"Zheyuan Technology provides AI pharmaceutical R&D solutions. Incubated by the Chinese Academy of Sciences’ Institute of Computing Technology, it is a platform company using digital life technology for pharmaceutical innovation. Its digital twins of life functions systematically propose new tumor targets, evaluate promising indications and predict responding patients. It aims to build a digital drug testing ground that overcomes biochemical bottlenecks, improves drug R&D productivity, clinical trial success and treatment effectiveness, and introduces a new R&D paradigm to protect human health. It holds high-value intellectual property in new targets, indications and companion diagnostics.","country":null,"category":"Health management","originalName":"哲源科技","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-20T05:00:22.447Z","englishUpdatedAt":"2026-10-20T18:29:36.222Z","reviewedAt":"2026-10-20T18:29:36.222Z","snapshotAt":"2026-10-20T18:06:34.551Z","sourceHash":"8de4712038967a6ebb5902b7adc16e3541c9bd18e6896f35d179f95f8c13b2b0","companyId":"379cea5b-ef8c-4bca-a8e9-dac76fb4710d","foundedYear":null,"logoUrl":null,"path":"/products/zheyuankeji"},{"id":"92273985-daa1-4ed1-b5cd-8933750bb10a","kind":"institutions","code":"UB-I681","name":"中科创星","nameBasis":"transliterated","summary":"An early-stage hard technology investment firm with a Chinese Academy of Sciences background, focused on research commercialization.","description":"An early-stage hard technology investment firm with a Chinese Academy of Sciences background, focused on research commercialization.","country":null,"category":null,"originalName":"中科创星","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T10:56:17.629Z","englishUpdatedAt":"2026-10-15T21:15:05.833Z","reviewedAt":"2026-10-15T21:15:05.833Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"e6f96e51233aef3001e47142703ac61241d704d3753ada1ee6bb93f4f99830bc","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Zhongkechuangxing","path":"/institutions/zhongkechuangxing"},{"id":"fbca5a9d-228a-426d-8ee0-3645207f7491","kind":"institutions","code":"UB-I5944","name":"博行资本","nameBasis":"transliterated","summary":"Boxing Capital, a Chinese equity investment firm focused on equity investments in startup-stage technology companies.","description":"Boxing Capital, a Chinese equity investment firm focused on equity investments in startup-stage technology companies.","country":null,"category":null,"originalName":"博行资本","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:44:22.014Z","englishUpdatedAt":"2026-10-15T21:31:30.067Z","reviewedAt":"2026-10-15T21:31:30.067Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"a99b4438536406342208ab66b447db65bbbb6bbd9f06c3b8c7a7f5e3b49a0a70","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Boxing Capital","path":"/institutions/boxing-capital"},{"id":"52305fa1-aaae-4a0f-be61-03fc840767d2","kind":"institutions","code":"UB-I9068","name":"圣湘生物","nameBasis":"transliterated","summary":"","description":"","country":null,"category":null,"originalName":"圣湘生物","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T15:36:30.631Z","englishUpdatedAt":"2026-10-15T17:35:39.000Z","reviewedAt":"2026-10-15T17:35:39.000Z","snapshotAt":"2026-10-15T16:06:35.585Z","sourceHash":"5d363e0d2e8424a02f42979e89461bdd307e7534d52d191ca65189cf57d5af19","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Shengxiang Biotechnology","path":"/institutions/shengxiang-biotechnology"},{"id":"9f82cadb-1a55-4fc2-846f-2e088b4e071d","kind":"institutions","code":"UB-I9113","name":"圣维荣泉","nameBasis":"transliterated","summary":"","description":"","country":null,"category":null,"originalName":"圣维荣泉","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T15:44:20.405Z","englishUpdatedAt":"2026-10-15T17:35:39.500Z","reviewedAt":"2026-10-15T17:35:39.500Z","snapshotAt":"2026-10-15T16:06:35.585Z","sourceHash":"f1ffc55144b08b8c6ce6d4b1d57e1cfc23f6bcfe1be7aee82cb0f3a982050dc6","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Shengweirongquan","path":"/institutions/shengweirongquan"},{"id":"4dadf873-1c55-44cf-a3fb-3a46ffb67c3e","kind":"institutions","code":"UB-I1977","name":"张江科投","nameBasis":"transliterated","summary":"Shanghai Zhangjiang Technology Venture Investment Co., Ltd.","description":"Shanghai Zhangjiang Technology Venture Investment Co., Ltd.","country":null,"category":null,"originalName":"张江科投","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T10:56:23.056Z","englishUpdatedAt":"2026-10-15T20:18:30.553Z","reviewedAt":"2026-10-15T20:18:30.553Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"4d85f1d77b19f8a655e99a996bfb12e5c9a455c9048882035818919e1c83eacb","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Zhangjiangketou","path":"/institutions/zhangjiangketou"},{"id":"665ccc2d-256d-41cf-8b63-1f626acf329b","kind":"institutions","code":"UB-I3936","name":"拓海鸿方","nameBasis":"transliterated","summary":"Tuohaihongfang is a Chinese private equity firm, focused on equity investment in growth-stage and mature unlisted companies.","description":"Tuohaihongfang is a Chinese private equity firm, focused on equity investment in growth-stage and mature unlisted companies.","country":null,"category":null,"originalName":"拓海鸿方","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:46:29.265Z","englishUpdatedAt":"2026-10-15T18:43:03.648Z","reviewedAt":"2026-10-15T18:43:03.648Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"674d24ee26833041d1b6e790f92d45d3df138a62a097be47c45f3b668871c3a1","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Tuohaihongfang","path":"/institutions/tuohaihongfang"},{"id":"41094ea3-9968-479c-91be-cacf6e6694b5","kind":"institutions","code":"UB-I5933","name":"泰雅资本","nameBasis":"transliterated","summary":"Taiya Capital, a Chinese venture capital firm focused on the growth of startup-stage enterprises.","description":"Taiya Capital, a Chinese venture capital firm focused on the growth of startup-stage enterprises.","country":null,"category":null,"originalName":"泰雅资本","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:44:21.925Z","englishUpdatedAt":"2026-10-15T21:21:01.639Z","reviewedAt":"2026-10-15T21:21:01.639Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"fa982697936e36fde686880eb755c31b1121ef9c783be8db22da96bd01531643","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Taiya Capital","path":"/institutions/taiya-capital"},{"id":"a6d5909a-f77e-428b-ab11-addb5447c2aa","kind":"institutions","code":"UB-I5926","name":"海金格医药","nameBasis":"transliterated","summary":"Haijinge Pharmaceutical, an investor using its parent company’s industry resources and corporate capital to invest in early-stage ventures.","description":"Haijinge Pharmaceutical, an investor using its parent company’s industry resources and corporate capital to invest in early-stage ventures.","country":null,"category":null,"originalName":"海金格医药","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:44:21.863Z","englishUpdatedAt":"2026-10-15T17:35:39.539Z","reviewedAt":"2026-10-15T17:35:39.539Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"ec5fd16fcdc93838b75c80ab49d3a5001142c961c8225d64cb2a012d94726c7a","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Haijinge Pharmaceutical","path":"/institutions/haijinge-pharmaceutical"},{"id":"95afd5a1-bc98-472b-bb78-bf6660de6b29","kind":"institutions","code":"UB-I5913","name":"诺禾致源","nameBasis":"transliterated","summary":"Nuohezhiyuan, a Chinese corporate-backed industrial investor making strategic investments in startups.","description":"Nuohezhiyuan, a Chinese corporate-backed industrial investor making strategic investments in startups.","country":null,"category":null,"originalName":"诺禾致源","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:44:21.735Z","englishUpdatedAt":"2026-10-15T17:35:39.429Z","reviewedAt":"2026-10-15T17:35:39.429Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"65e541dc028ce137a86da357f46ca0504838ab9176c846223e6d333f09efebb7","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Nuohezhiyuan","path":"/institutions/nuohezhiyuan"}],"finance":{"funding":{"metric":"funding","count":3,"latest":{"value":28571428,"text":"2亿人民币","date":"2026-03-12T00:00:00.000Z","round":"Series A+","estimate":"RMB 200M"},"years":[2022,2026],"points":[{"year":2022,"date":"2022-06-15T00:00:00.000Z","round":"Series A","value":14285714,"eventIds":["3d5c8a2a-7746-46ea-adaf-535bc0ef27ae"]},{"year":2026,"date":"2026-03-12T00:00:00.000Z","round":"Series A+","value":28571428,"eventIds":["0c87ff00-553b-47b8-bb6e-472130f54a45"]}],"linePoints":[],"conflictGroups":0,"omittedRecordCount":1,"records":[{"id":"0c87ff00-553b-47b8-bb6e-472130f54a45","date":"2026-03-12T00:00:00.000Z","round":"Series A+","amountText":"2亿人民币","estimateUsd":28571428,"estimateLabel":"RMB 200M","estimateNote":"≈ $28.6M","investors":"圣湘生物,圣维荣泉,张江科投,中科创星","institutions":[{"id":"92273985-daa1-4ed1-b5cd-8933750bb10a","kind":"institutions","code":"UB-I681","name":"中科创星","nameBasis":"transliterated","summary":"An early-stage hard technology investment firm with a Chinese Academy of Sciences background, focused on research commercialization.","description":"An early-stage hard technology investment firm with a Chinese Academy of Sciences background, focused on research commercialization.","country":null,"category":null,"originalName":"中科创星","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T10:56:17.629Z","englishUpdatedAt":"2026-10-15T21:15:05.833Z","reviewedAt":"2026-10-15T21:15:05.833Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"e6f96e51233aef3001e47142703ac61241d704d3753ada1ee6bb93f4f99830bc","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Zhongkechuangxing","path":"/institutions/zhongkechuangxing"},{"id":"52305fa1-aaae-4a0f-be61-03fc840767d2","kind":"institutions","code":"UB-I9068","name":"圣湘生物","nameBasis":"transliterated","summary":"","description":"","country":null,"category":null,"originalName":"圣湘生物","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T15:36:30.631Z","englishUpdatedAt":"2026-10-15T17:35:39.000Z","reviewedAt":"2026-10-15T17:35:39.000Z","snapshotAt":"2026-10-15T16:06:35.585Z","sourceHash":"5d363e0d2e8424a02f42979e89461bdd307e7534d52d191ca65189cf57d5af19","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Shengxiang Biotechnology","path":"/institutions/shengxiang-biotechnology"},{"id":"9f82cadb-1a55-4fc2-846f-2e088b4e071d","kind":"institutions","code":"UB-I9113","name":"圣维荣泉","nameBasis":"transliterated","summary":"","description":"","country":null,"category":null,"originalName":"圣维荣泉","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T15:44:20.405Z","englishUpdatedAt":"2026-10-15T17:35:39.500Z","reviewedAt":"2026-10-15T17:35:39.500Z","snapshotAt":"2026-10-15T16:06:35.585Z","sourceHash":"f1ffc55144b08b8c6ce6d4b1d57e1cfc23f6bcfe1be7aee82cb0f3a982050dc6","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Shengweirongquan","path":"/institutions/shengweirongquan"},{"id":"4dadf873-1c55-44cf-a3fb-3a46ffb67c3e","kind":"institutions","code":"UB-I1977","name":"张江科投","nameBasis":"transliterated","summary":"Shanghai Zhangjiang Technology Venture Investment Co., Ltd.","description":"Shanghai Zhangjiang Technology Venture Investment Co., Ltd.","country":null,"category":null,"originalName":"张江科投","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T10:56:23.056Z","englishUpdatedAt":"2026-10-15T20:18:30.553Z","reviewedAt":"2026-10-15T20:18:30.553Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"4d85f1d77b19f8a655e99a996bfb12e5c9a455c9048882035818919e1c83eacb","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Zhangjiangketou","path":"/institutions/zhangjiangketou"}],"newsUrl":null,"evidence":{"headline":"Phil Rivers raises RMB 200 million in Series A+ financing","brief":"On 2026-03-12, according to Xiniu Data, Phil Rivers completed Series A+ financing, raising RMB 200 million. Investors were Shengxiang Biotechnology, Shengweirongquan, Zhangjiangketou, Zhongkechuangxing.","basis":"translated-source-brief","newsPath":"/news/0c87ff00-553b-47b8-bb6e-472130f54a45","sourceCount":0}},{"id":"b515d63e-5a11-48b6-91c5-b93a47540d5e","date":"2024-12-12T00:00:00.000Z","round":"Strategic","amountText":"未披露","estimateUsd":null,"estimateLabel":"Undisclosed","estimateNote":null,"investors":"拓海鸿方","institutions":[{"id":"665ccc2d-256d-41cf-8b63-1f626acf329b","kind":"institutions","code":"UB-I3936","name":"拓海鸿方","nameBasis":"transliterated","summary":"Tuohaihongfang is a Chinese private equity firm, focused on equity investment in growth-stage and mature unlisted companies.","description":"Tuohaihongfang is a Chinese private equity firm, focused on equity investment in growth-stage and mature unlisted companies.","country":null,"category":null,"originalName":"拓海鸿方","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:46:29.265Z","englishUpdatedAt":"2026-10-15T18:43:03.648Z","reviewedAt":"2026-10-15T18:43:03.648Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"674d24ee26833041d1b6e790f92d45d3df138a62a097be47c45f3b668871c3a1","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Tuohaihongfang","path":"/institutions/tuohaihongfang"}],"newsUrl":null,"evidence":{"headline":"Phil Rivers completes strategic financing","brief":null,"basis":null,"newsPath":"/news/b515d63e-5a11-48b6-91c5-b93a47540d5e","sourceCount":0}},{"id":"3d5c8a2a-7746-46ea-adaf-535bc0ef27ae","date":"2022-06-15T00:00:00.000Z","round":"Series A","amountText":"1亿人民币","estimateUsd":14285714,"estimateLabel":"RMB 100M","estimateNote":"≈ $14.3M","investors":"博行资本,泰雅资本,海金格医药,诺禾致源","institutions":[{"id":"fbca5a9d-228a-426d-8ee0-3645207f7491","kind":"institutions","code":"UB-I5944","name":"博行资本","nameBasis":"transliterated","summary":"Boxing Capital, a Chinese equity investment firm focused on equity investments in startup-stage technology companies.","description":"Boxing Capital, a Chinese equity investment firm focused on equity investments in startup-stage technology companies.","country":null,"category":null,"originalName":"博行资本","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:44:22.014Z","englishUpdatedAt":"2026-10-15T21:31:30.067Z","reviewedAt":"2026-10-15T21:31:30.067Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"a99b4438536406342208ab66b447db65bbbb6bbd9f06c3b8c7a7f5e3b49a0a70","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Boxing Capital","path":"/institutions/boxing-capital"},{"id":"41094ea3-9968-479c-91be-cacf6e6694b5","kind":"institutions","code":"UB-I5933","name":"泰雅资本","nameBasis":"transliterated","summary":"Taiya Capital, a Chinese venture capital firm focused on the growth of startup-stage enterprises.","description":"Taiya Capital, a Chinese venture capital firm focused on the growth of startup-stage enterprises.","country":null,"category":null,"originalName":"泰雅资本","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:44:21.925Z","englishUpdatedAt":"2026-10-15T21:21:01.639Z","reviewedAt":"2026-10-15T21:21:01.639Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"fa982697936e36fde686880eb755c31b1121ef9c783be8db22da96bd01531643","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Taiya Capital","path":"/institutions/taiya-capital"},{"id":"a6d5909a-f77e-428b-ab11-addb5447c2aa","kind":"institutions","code":"UB-I5926","name":"海金格医药","nameBasis":"transliterated","summary":"Haijinge Pharmaceutical, an investor using its parent company’s industry resources and corporate capital to invest in early-stage ventures.","description":"Haijinge Pharmaceutical, an investor using its parent company’s industry resources and corporate capital to invest in early-stage ventures.","country":null,"category":null,"originalName":"海金格医药","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:44:21.863Z","englishUpdatedAt":"2026-10-15T17:35:39.539Z","reviewedAt":"2026-10-15T17:35:39.539Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"ec5fd16fcdc93838b75c80ab49d3a5001142c961c8225d64cb2a012d94726c7a","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Haijinge Pharmaceutical","path":"/institutions/haijinge-pharmaceutical"},{"id":"95afd5a1-bc98-472b-bb78-bf6660de6b29","kind":"institutions","code":"UB-I5913","name":"诺禾致源","nameBasis":"transliterated","summary":"Nuohezhiyuan, a Chinese corporate-backed industrial investor making strategic investments in startups.","description":"Nuohezhiyuan, a Chinese corporate-backed industrial investor making strategic investments in startups.","country":null,"category":null,"originalName":"诺禾致源","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:44:21.735Z","englishUpdatedAt":"2026-10-15T17:35:39.429Z","reviewedAt":"2026-10-15T17:35:39.429Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"65e541dc028ce137a86da357f46ca0504838ab9176c846223e6d333f09efebb7","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Nuohezhiyuan","path":"/institutions/nuohezhiyuan"}],"newsUrl":null,"evidence":{"headline":"Phil Rivers raises RMB 100 million in Series A financing","brief":null,"basis":null,"newsPath":"/news/3d5c8a2a-7746-46ea-adaf-535bc0ef27ae","sourceCount":0}}],"totalRaised":null},"valuation":{"metric":"valuation","count":3,"latest":null,"years":[],"points":[],"linePoints":[],"conflictGroups":0,"omittedRecordCount":3,"records":[{"id":"0c87ff00-553b-47b8-bb6e-472130f54a45","date":"2026-03-12T00:00:00.000Z","round":"Series A+","amountText":null,"estimateUsd":null,"estimateLabel":null,"estimateNote":null,"investors":"圣湘生物,圣维荣泉,张江科投,中科创星","institutions":[{"id":"92273985-daa1-4ed1-b5cd-8933750bb10a","kind":"institutions","code":"UB-I681","name":"中科创星","nameBasis":"transliterated","summary":"An early-stage hard technology investment firm with a Chinese Academy of Sciences background, focused on research commercialization.","description":"An early-stage hard technology investment firm with a Chinese Academy of Sciences background, focused on research commercialization.","country":null,"category":null,"originalName":"中科创星","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T10:56:17.629Z","englishUpdatedAt":"2026-10-15T21:15:05.833Z","reviewedAt":"2026-10-15T21:15:05.833Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"e6f96e51233aef3001e47142703ac61241d704d3753ada1ee6bb93f4f99830bc","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Zhongkechuangxing","path":"/institutions/zhongkechuangxing"},{"id":"52305fa1-aaae-4a0f-be61-03fc840767d2","kind":"institutions","code":"UB-I9068","name":"圣湘生物","nameBasis":"transliterated","summary":"","description":"","country":null,"category":null,"originalName":"圣湘生物","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T15:36:30.631Z","englishUpdatedAt":"2026-10-15T17:35:39.000Z","reviewedAt":"2026-10-15T17:35:39.000Z","snapshotAt":"2026-10-15T16:06:35.585Z","sourceHash":"5d363e0d2e8424a02f42979e89461bdd307e7534d52d191ca65189cf57d5af19","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Shengxiang Biotechnology","path":"/institutions/shengxiang-biotechnology"},{"id":"9f82cadb-1a55-4fc2-846f-2e088b4e071d","kind":"institutions","code":"UB-I9113","name":"圣维荣泉","nameBasis":"transliterated","summary":"","description":"","country":null,"category":null,"originalName":"圣维荣泉","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T15:44:20.405Z","englishUpdatedAt":"2026-10-15T17:35:39.500Z","reviewedAt":"2026-10-15T17:35:39.500Z","snapshotAt":"2026-10-15T16:06:35.585Z","sourceHash":"f1ffc55144b08b8c6ce6d4b1d57e1cfc23f6bcfe1be7aee82cb0f3a982050dc6","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Shengweirongquan","path":"/institutions/shengweirongquan"},{"id":"4dadf873-1c55-44cf-a3fb-3a46ffb67c3e","kind":"institutions","code":"UB-I1977","name":"张江科投","nameBasis":"transliterated","summary":"Shanghai Zhangjiang Technology Venture Investment Co., Ltd.","description":"Shanghai Zhangjiang Technology Venture Investment Co., Ltd.","country":null,"category":null,"originalName":"张江科投","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T10:56:23.056Z","englishUpdatedAt":"2026-10-15T20:18:30.553Z","reviewedAt":"2026-10-15T20:18:30.553Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"4d85f1d77b19f8a655e99a996bfb12e5c9a455c9048882035818919e1c83eacb","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Zhangjiangketou","path":"/institutions/zhangjiangketou"}],"newsUrl":null,"evidence":{"headline":"Phil Rivers raises RMB 200 million in Series A+ financing","brief":"On 2026-03-12, according to Xiniu Data, Phil Rivers completed Series A+ financing, raising RMB 200 million. Investors were Shengxiang Biotechnology, Shengweirongquan, Zhangjiangketou, Zhongkechuangxing.","basis":"translated-source-brief","newsPath":"/news/0c87ff00-553b-47b8-bb6e-472130f54a45","sourceCount":0}},{"id":"b515d63e-5a11-48b6-91c5-b93a47540d5e","date":"2024-12-12T00:00:00.000Z","round":"Strategic","amountText":null,"estimateUsd":null,"estimateLabel":null,"estimateNote":null,"investors":"拓海鸿方","institutions":[{"id":"665ccc2d-256d-41cf-8b63-1f626acf329b","kind":"institutions","code":"UB-I3936","name":"拓海鸿方","nameBasis":"transliterated","summary":"Tuohaihongfang is a Chinese private equity firm, focused on equity investment in growth-stage and mature unlisted companies.","description":"Tuohaihongfang is a Chinese private equity firm, focused on equity investment in growth-stage and mature unlisted companies.","country":null,"category":null,"originalName":"拓海鸿方","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:46:29.265Z","englishUpdatedAt":"2026-10-15T18:43:03.648Z","reviewedAt":"2026-10-15T18:43:03.648Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"674d24ee26833041d1b6e790f92d45d3df138a62a097be47c45f3b668871c3a1","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Tuohaihongfang","path":"/institutions/tuohaihongfang"}],"newsUrl":null,"evidence":{"headline":"Phil Rivers completes strategic financing","brief":null,"basis":null,"newsPath":"/news/b515d63e-5a11-48b6-91c5-b93a47540d5e","sourceCount":0}},{"id":"3d5c8a2a-7746-46ea-adaf-535bc0ef27ae","date":"2022-06-15T00:00:00.000Z","round":"Series A","amountText":null,"estimateUsd":null,"estimateLabel":null,"estimateNote":null,"investors":"博行资本,泰雅资本,海金格医药,诺禾致源","institutions":[{"id":"fbca5a9d-228a-426d-8ee0-3645207f7491","kind":"institutions","code":"UB-I5944","name":"博行资本","nameBasis":"transliterated","summary":"Boxing Capital, a Chinese equity investment firm focused on equity investments in startup-stage technology companies.","description":"Boxing Capital, a Chinese equity investment firm focused on equity investments in startup-stage technology companies.","country":null,"category":null,"originalName":"博行资本","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:44:22.014Z","englishUpdatedAt":"2026-10-15T21:31:30.067Z","reviewedAt":"2026-10-15T21:31:30.067Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"a99b4438536406342208ab66b447db65bbbb6bbd9f06c3b8c7a7f5e3b49a0a70","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Boxing Capital","path":"/institutions/boxing-capital"},{"id":"41094ea3-9968-479c-91be-cacf6e6694b5","kind":"institutions","code":"UB-I5933","name":"泰雅资本","nameBasis":"transliterated","summary":"Taiya Capital, a Chinese venture capital firm focused on the growth of startup-stage enterprises.","description":"Taiya Capital, a Chinese venture capital firm focused on the growth of startup-stage enterprises.","country":null,"category":null,"originalName":"泰雅资本","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:44:21.925Z","englishUpdatedAt":"2026-10-15T21:21:01.639Z","reviewedAt":"2026-10-15T21:21:01.639Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"fa982697936e36fde686880eb755c31b1121ef9c783be8db22da96bd01531643","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Taiya Capital","path":"/institutions/taiya-capital"},{"id":"a6d5909a-f77e-428b-ab11-addb5447c2aa","kind":"institutions","code":"UB-I5926","name":"海金格医药","nameBasis":"transliterated","summary":"Haijinge Pharmaceutical, an investor using its parent company’s industry resources and corporate capital to invest in early-stage ventures.","description":"Haijinge Pharmaceutical, an investor using its parent company’s industry resources and corporate capital to invest in early-stage ventures.","country":null,"category":null,"originalName":"海金格医药","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:44:21.863Z","englishUpdatedAt":"2026-10-15T17:35:39.539Z","reviewedAt":"2026-10-15T17:35:39.539Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"ec5fd16fcdc93838b75c80ab49d3a5001142c961c8225d64cb2a012d94726c7a","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Haijinge Pharmaceutical","path":"/institutions/haijinge-pharmaceutical"},{"id":"95afd5a1-bc98-472b-bb78-bf6660de6b29","kind":"institutions","code":"UB-I5913","name":"诺禾致源","nameBasis":"transliterated","summary":"Nuohezhiyuan, a Chinese corporate-backed industrial investor making strategic investments in startups.","description":"Nuohezhiyuan, a Chinese corporate-backed industrial investor making strategic investments in startups.","country":null,"category":null,"originalName":"诺禾致源","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:44:21.735Z","englishUpdatedAt":"2026-10-15T17:35:39.429Z","reviewedAt":"2026-10-15T17:35:39.429Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"65e541dc028ce137a86da357f46ca0504838ab9176c846223e6d333f09efebb7","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Nuohezhiyuan","path":"/institutions/nuohezhiyuan"}],"newsUrl":null,"evidence":{"headline":"Phil Rivers raises RMB 100 million in Series A financing","brief":null,"basis":null,"newsPath":"/news/3d5c8a2a-7746-46ea-adaf-535bc0ef27ae","sourceCount":0}}]},"revenue":{"metric":"revenue","count":0,"latest":null,"years":[],"points":[],"linePoints":[],"conflictGroups":0,"omittedRecordCount":0,"records":[]}},"events":[{"id":"0c87ff00-553b-47b8-bb6e-472130f54a45","kind":"funding","eventDate":"2026-03-12T00:00:00.000Z","revenueDate":null,"round":"A+轮","amountText":"2亿人民币","valuationText":null,"revenueText":"","cumulativeFundingText":"","amountEstimateUsd":28571428,"valuationEstimateUsd":null,"revenueEstimateUsd":null,"cumulativeFundingEstimateUsd":null,"investors":"圣湘生物,圣维荣泉,张江科投,中科创星","newsUrl":null,"newsTypes":["融资"],"institutions":[{"id":"92273985-daa1-4ed1-b5cd-8933750bb10a","kind":"institutions","code":"UB-I681","name":"中科创星","nameBasis":"transliterated","summary":"An early-stage hard technology investment firm with a Chinese Academy of Sciences background, focused on research commercialization.","description":"An early-stage hard technology investment firm with a Chinese Academy of Sciences background, focused on research commercialization.","country":null,"category":null,"originalName":"中科创星","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T10:56:17.629Z","englishUpdatedAt":"2026-10-15T21:15:05.833Z","reviewedAt":"2026-10-15T21:15:05.833Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"e6f96e51233aef3001e47142703ac61241d704d3753ada1ee6bb93f4f99830bc","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Zhongkechuangxing","path":"/institutions/zhongkechuangxing"},{"id":"52305fa1-aaae-4a0f-be61-03fc840767d2","kind":"institutions","code":"UB-I9068","name":"圣湘生物","nameBasis":"transliterated","summary":"","description":"","country":null,"category":null,"originalName":"圣湘生物","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T15:36:30.631Z","englishUpdatedAt":"2026-10-15T17:35:39.000Z","reviewedAt":"2026-10-15T17:35:39.000Z","snapshotAt":"2026-10-15T16:06:35.585Z","sourceHash":"5d363e0d2e8424a02f42979e89461bdd307e7534d52d191ca65189cf57d5af19","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Shengxiang Biotechnology","path":"/institutions/shengxiang-biotechnology"},{"id":"9f82cadb-1a55-4fc2-846f-2e088b4e071d","kind":"institutions","code":"UB-I9113","name":"圣维荣泉","nameBasis":"transliterated","summary":"","description":"","country":null,"category":null,"originalName":"圣维荣泉","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T15:44:20.405Z","englishUpdatedAt":"2026-10-15T17:35:39.500Z","reviewedAt":"2026-10-15T17:35:39.500Z","snapshotAt":"2026-10-15T16:06:35.585Z","sourceHash":"f1ffc55144b08b8c6ce6d4b1d57e1cfc23f6bcfe1be7aee82cb0f3a982050dc6","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Shengweirongquan","path":"/institutions/shengweirongquan"},{"id":"4dadf873-1c55-44cf-a3fb-3a46ffb67c3e","kind":"institutions","code":"UB-I1977","name":"张江科投","nameBasis":"transliterated","summary":"Shanghai Zhangjiang Technology Venture Investment Co., Ltd.","description":"Shanghai Zhangjiang Technology Venture Investment Co., Ltd.","country":null,"category":null,"originalName":"张江科投","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T10:56:23.056Z","englishUpdatedAt":"2026-10-15T20:18:30.553Z","reviewedAt":"2026-10-15T20:18:30.553Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"4d85f1d77b19f8a655e99a996bfb12e5c9a455c9048882035818919e1c83eacb","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Zhangjiangketou","path":"/institutions/zhangjiangketou"}],"roundName":"Series A+","amountLabel":"RMB 200M","valuationLabel":null,"revenueLabel":null,"cumulativeFundingLabel":null},{"id":"b515d63e-5a11-48b6-91c5-b93a47540d5e","kind":"funding","eventDate":"2024-12-12T00:00:00.000Z","revenueDate":null,"round":"战略投资","amountText":"未披露","valuationText":null,"revenueText":"","cumulativeFundingText":"","amountEstimateUsd":null,"valuationEstimateUsd":null,"revenueEstimateUsd":null,"cumulativeFundingEstimateUsd":null,"investors":"拓海鸿方","newsUrl":null,"newsTypes":["融资"],"institutions":[{"id":"665ccc2d-256d-41cf-8b63-1f626acf329b","kind":"institutions","code":"UB-I3936","name":"拓海鸿方","nameBasis":"transliterated","summary":"Tuohaihongfang is a Chinese private equity firm, focused on equity investment in growth-stage and mature unlisted companies.","description":"Tuohaihongfang is a Chinese private equity firm, focused on equity investment in growth-stage and mature unlisted companies.","country":null,"category":null,"originalName":"拓海鸿方","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:46:29.265Z","englishUpdatedAt":"2026-10-15T18:43:03.648Z","reviewedAt":"2026-10-15T18:43:03.648Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"674d24ee26833041d1b6e790f92d45d3df138a62a097be47c45f3b668871c3a1","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Tuohaihongfang","path":"/institutions/tuohaihongfang"}],"roundName":"Strategic","amountLabel":"Undisclosed","valuationLabel":null,"revenueLabel":null,"cumulativeFundingLabel":null},{"id":"3d5c8a2a-7746-46ea-adaf-535bc0ef27ae","kind":"funding","eventDate":"2022-06-15T00:00:00.000Z","revenueDate":null,"round":"A轮","amountText":"1亿人民币","valuationText":null,"revenueText":"","cumulativeFundingText":"","amountEstimateUsd":14285714,"valuationEstimateUsd":null,"revenueEstimateUsd":null,"cumulativeFundingEstimateUsd":null,"investors":"博行资本,泰雅资本,海金格医药,诺禾致源","newsUrl":null,"newsTypes":["融资"],"institutions":[{"id":"fbca5a9d-228a-426d-8ee0-3645207f7491","kind":"institutions","code":"UB-I5944","name":"博行资本","nameBasis":"transliterated","summary":"Boxing Capital, a Chinese equity investment firm focused on equity investments in startup-stage technology companies.","description":"Boxing Capital, a Chinese equity investment firm focused on equity investments in startup-stage technology companies.","country":null,"category":null,"originalName":"博行资本","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:44:22.014Z","englishUpdatedAt":"2026-10-15T21:31:30.067Z","reviewedAt":"2026-10-15T21:31:30.067Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"a99b4438536406342208ab66b447db65bbbb6bbd9f06c3b8c7a7f5e3b49a0a70","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Boxing Capital","path":"/institutions/boxing-capital"},{"id":"41094ea3-9968-479c-91be-cacf6e6694b5","kind":"institutions","code":"UB-I5933","name":"泰雅资本","nameBasis":"transliterated","summary":"Taiya Capital, a Chinese venture capital firm focused on the growth of startup-stage enterprises.","description":"Taiya Capital, a Chinese venture capital firm focused on the growth of startup-stage enterprises.","country":null,"category":null,"originalName":"泰雅资本","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:44:21.925Z","englishUpdatedAt":"2026-10-15T21:21:01.639Z","reviewedAt":"2026-10-15T21:21:01.639Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"fa982697936e36fde686880eb755c31b1121ef9c783be8db22da96bd01531643","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Taiya Capital","path":"/institutions/taiya-capital"},{"id":"a6d5909a-f77e-428b-ab11-addb5447c2aa","kind":"institutions","code":"UB-I5926","name":"海金格医药","nameBasis":"transliterated","summary":"Haijinge Pharmaceutical, an investor using its parent company’s industry resources and corporate capital to invest in early-stage ventures.","description":"Haijinge Pharmaceutical, an investor using its parent company’s industry resources and corporate capital to invest in early-stage ventures.","country":null,"category":null,"originalName":"海金格医药","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:44:21.863Z","englishUpdatedAt":"2026-10-15T17:35:39.539Z","reviewedAt":"2026-10-15T17:35:39.539Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"ec5fd16fcdc93838b75c80ab49d3a5001142c961c8225d64cb2a012d94726c7a","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Haijinge Pharmaceutical","path":"/institutions/haijinge-pharmaceutical"},{"id":"95afd5a1-bc98-472b-bb78-bf6660de6b29","kind":"institutions","code":"UB-I5913","name":"诺禾致源","nameBasis":"transliterated","summary":"Nuohezhiyuan, a Chinese corporate-backed industrial investor making strategic investments in startups.","description":"Nuohezhiyuan, a Chinese corporate-backed industrial investor making strategic investments in startups.","country":null,"category":null,"originalName":"诺禾致源","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:44:21.735Z","englishUpdatedAt":"2026-10-15T17:35:39.429Z","reviewedAt":"2026-10-15T17:35:39.429Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"65e541dc028ce137a86da357f46ca0504838ab9176c846223e6d333f09efebb7","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Nuohezhiyuan","path":"/institutions/nuohezhiyuan"}],"roundName":"Series A","amountLabel":"RMB 100M","valuationLabel":null,"revenueLabel":null,"cumulativeFundingLabel":null}],"team":[],"productsRelated":[{"id":"2d71f315-d801-4dda-a133-bdf72aa26d08","kind":"products","code":"UB-D471","name":"Zheyuan Technology","nameBasis":"transliterated","summary":"Zheyuan Technology provides AI pharmaceutical R&D solutions. Incubated by the Chinese Academy of Sciences’ Institute of Computing Technology, it is a platform company using digital life technology for pharmaceutical innovation. Its digital twins of life functions systematically propose new tumor targets, evaluate promising indications and predict responding patients. It aims to build a digital drug testing ground that overcomes biochemical bottlenecks, improves drug R&D productivity, clinical trial success and treatment effectiveness, and introduces a new R&D paradigm to protect human health. It holds high-value intellectual property in new targets, indications and companion diagnostics.","description":"Zheyuan Technology provides AI pharmaceutical R&D solutions. Incubated by the Chinese Academy of Sciences’ Institute of Computing Technology, it is a platform company using digital life technology for pharmaceutical innovation. Its digital twins of life functions systematically propose new tumor targets, evaluate promising indications and predict responding patients. It aims to build a digital drug testing ground that overcomes biochemical bottlenecks, improves drug R&D productivity, clinical trial success and treatment effectiveness, and introduces a new R&D paradigm to protect human health. It holds high-value intellectual property in new targets, indications and companion diagnostics.","country":null,"category":"Health management","originalName":"哲源科技","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-20T05:00:22.447Z","englishUpdatedAt":"2026-10-20T18:29:36.222Z","reviewedAt":"2026-10-20T18:29:36.222Z","snapshotAt":"2026-10-20T18:06:34.551Z","sourceHash":"8de4712038967a6ebb5902b7adc16e3541c9bd18e6896f35d179f95f8c13b2b0","companyId":"379cea5b-ef8c-4bca-a8e9-dac76fb4710d","foundedYear":null,"logoUrl":null,"path":"/products/zheyuankeji"}],"investors":[{"id":"92273985-daa1-4ed1-b5cd-8933750bb10a","kind":"institutions","code":"UB-I681","name":"中科创星","nameBasis":"transliterated","summary":"An early-stage hard technology investment firm with a Chinese Academy of Sciences background, focused on research commercialization.","description":"An early-stage hard technology investment firm with a Chinese Academy of Sciences background, focused on research commercialization.","country":null,"category":null,"originalName":"中科创星","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T10:56:17.629Z","englishUpdatedAt":"2026-10-15T21:15:05.833Z","reviewedAt":"2026-10-15T21:15:05.833Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"e6f96e51233aef3001e47142703ac61241d704d3753ada1ee6bb93f4f99830bc","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Zhongkechuangxing","path":"/institutions/zhongkechuangxing"},{"id":"fbca5a9d-228a-426d-8ee0-3645207f7491","kind":"institutions","code":"UB-I5944","name":"博行资本","nameBasis":"transliterated","summary":"Boxing Capital, a Chinese equity investment firm focused on equity investments in startup-stage technology companies.","description":"Boxing Capital, a Chinese equity investment firm focused on equity investments in startup-stage technology companies.","country":null,"category":null,"originalName":"博行资本","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:44:22.014Z","englishUpdatedAt":"2026-10-15T21:31:30.067Z","reviewedAt":"2026-10-15T21:31:30.067Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"a99b4438536406342208ab66b447db65bbbb6bbd9f06c3b8c7a7f5e3b49a0a70","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Boxing Capital","path":"/institutions/boxing-capital"},{"id":"52305fa1-aaae-4a0f-be61-03fc840767d2","kind":"institutions","code":"UB-I9068","name":"圣湘生物","nameBasis":"transliterated","summary":"","description":"","country":null,"category":null,"originalName":"圣湘生物","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T15:36:30.631Z","englishUpdatedAt":"2026-10-15T17:35:39.000Z","reviewedAt":"2026-10-15T17:35:39.000Z","snapshotAt":"2026-10-15T16:06:35.585Z","sourceHash":"5d363e0d2e8424a02f42979e89461bdd307e7534d52d191ca65189cf57d5af19","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Shengxiang Biotechnology","path":"/institutions/shengxiang-biotechnology"},{"id":"9f82cadb-1a55-4fc2-846f-2e088b4e071d","kind":"institutions","code":"UB-I9113","name":"圣维荣泉","nameBasis":"transliterated","summary":"","description":"","country":null,"category":null,"originalName":"圣维荣泉","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T15:44:20.405Z","englishUpdatedAt":"2026-10-15T17:35:39.500Z","reviewedAt":"2026-10-15T17:35:39.500Z","snapshotAt":"2026-10-15T16:06:35.585Z","sourceHash":"f1ffc55144b08b8c6ce6d4b1d57e1cfc23f6bcfe1be7aee82cb0f3a982050dc6","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Shengweirongquan","path":"/institutions/shengweirongquan"},{"id":"4dadf873-1c55-44cf-a3fb-3a46ffb67c3e","kind":"institutions","code":"UB-I1977","name":"张江科投","nameBasis":"transliterated","summary":"Shanghai Zhangjiang Technology Venture Investment Co., Ltd.","description":"Shanghai Zhangjiang Technology Venture Investment Co., Ltd.","country":null,"category":null,"originalName":"张江科投","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T10:56:23.056Z","englishUpdatedAt":"2026-10-15T20:18:30.553Z","reviewedAt":"2026-10-15T20:18:30.553Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"4d85f1d77b19f8a655e99a996bfb12e5c9a455c9048882035818919e1c83eacb","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Zhangjiangketou","path":"/institutions/zhangjiangketou"},{"id":"665ccc2d-256d-41cf-8b63-1f626acf329b","kind":"institutions","code":"UB-I3936","name":"拓海鸿方","nameBasis":"transliterated","summary":"Tuohaihongfang is a Chinese private equity firm, focused on equity investment in growth-stage and mature unlisted companies.","description":"Tuohaihongfang is a Chinese private equity firm, focused on equity investment in growth-stage and mature unlisted companies.","country":null,"category":null,"originalName":"拓海鸿方","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:46:29.265Z","englishUpdatedAt":"2026-10-15T18:43:03.648Z","reviewedAt":"2026-10-15T18:43:03.648Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"674d24ee26833041d1b6e790f92d45d3df138a62a097be47c45f3b668871c3a1","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Tuohaihongfang","path":"/institutions/tuohaihongfang"},{"id":"41094ea3-9968-479c-91be-cacf6e6694b5","kind":"institutions","code":"UB-I5933","name":"泰雅资本","nameBasis":"transliterated","summary":"Taiya Capital, a Chinese venture capital firm focused on the growth of startup-stage enterprises.","description":"Taiya Capital, a Chinese venture capital firm focused on the growth of startup-stage enterprises.","country":null,"category":null,"originalName":"泰雅资本","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:44:21.925Z","englishUpdatedAt":"2026-10-15T21:21:01.639Z","reviewedAt":"2026-10-15T21:21:01.639Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"fa982697936e36fde686880eb755c31b1121ef9c783be8db22da96bd01531643","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Taiya Capital","path":"/institutions/taiya-capital"},{"id":"a6d5909a-f77e-428b-ab11-addb5447c2aa","kind":"institutions","code":"UB-I5926","name":"海金格医药","nameBasis":"transliterated","summary":"Haijinge Pharmaceutical, an investor using its parent company’s industry resources and corporate capital to invest in early-stage ventures.","description":"Haijinge Pharmaceutical, an investor using its parent company’s industry resources and corporate capital to invest in early-stage ventures.","country":null,"category":null,"originalName":"海金格医药","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:44:21.863Z","englishUpdatedAt":"2026-10-15T17:35:39.539Z","reviewedAt":"2026-10-15T17:35:39.539Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"ec5fd16fcdc93838b75c80ab49d3a5001142c961c8225d64cb2a012d94726c7a","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Haijinge Pharmaceutical","path":"/institutions/haijinge-pharmaceutical"},{"id":"95afd5a1-bc98-472b-bb78-bf6660de6b29","kind":"institutions","code":"UB-I5913","name":"诺禾致源","nameBasis":"transliterated","summary":"Nuohezhiyuan, a Chinese corporate-backed industrial investor making strategic investments in startups.","description":"Nuohezhiyuan, a Chinese corporate-backed industrial investor making strategic investments in startups.","country":null,"category":null,"originalName":"诺禾致源","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:44:21.735Z","englishUpdatedAt":"2026-10-15T17:35:39.429Z","reviewedAt":"2026-10-15T17:35:39.429Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"65e541dc028ce137a86da357f46ca0504838ab9176c846223e6d333f09efebb7","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Nuohezhiyuan","path":"/institutions/nuohezhiyuan"}],"path":"/companies/zheyuankeji","structured":{"city":"Beijing","country":"China","location":null,"role":null,"category":null,"company":null},"definition":"Phil Rivers is a company in the Industry apps sector headquartered in Beijing, China.","summaryBasis":"translated","thin":false,"canonical":"https://uniquebase.ai/companies/zheyuankeji"}